arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Summit Therapeutics Inc.

SMMT
$13.96 ▲ +0.42 (+3.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Summit Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.9B
Dividend Yield
Revenue Growth None
Op. Margin
ROIC None
FCF / Share $-0.18
Trailing P/E
Price / Book 17.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-189.42M
↓ -201.1%
FCF / Share Free cash flow per share
$-0.18
↓ -15.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Cash Quality
32

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters